Drug Information

Drug General Information
Drug ID
D06PFT
Former ID
DCL000622
Drug Name
Rhumab Beta7
Drug Type
Antibody
Indication Ulcerative colitis [ICD9: 556; ICD10:K51] Phase 3 [548506]
Company
Roche; Genentech
Target and Pathway
Target(s) Integrin beta-7 Target Info [531945], [550797]
KEGG Pathway PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Cell adhesion molecules (CAMs)
Intestinal immune network for IgA production
Regulation of actin cytoskeleton
Transcriptional misregulation in cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
NetPath Pathway IL2 Signaling Pathway
Wnt Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Integrin signalling pathway
Pathway Interaction Database Integrin family cell surface interactions
AlphaE beta7 integrin cell surface interactions
E-cadherin signaling in the nascent adherens junction
a4b7 Integrin signaling
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Integrin cell surface interactions
WikiPathways Focal Adhesion
Arrhythmogenic Right Ventricular Cardiomyopathy
Integrin-mediated Cell Adhesion
Integrin cell surface interactions
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 548506Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026082)
Ref 531945A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122-30.
Ref 550797Clinical pipeline report, company report or official report of Genentech (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.